Search Results - "Houyau, Philippe"

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier-Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Chauvenet, Marion, Kianmanesh, Reza, Fonck, Marianne, Houyau, Philippe, Aparicio, Thomas, Galais, Marie-Pierre, Audemar, Franck, Assenat, Eric, Lopez-Crapez, Evelyne, Jouffroy, Claire, Adenis, Antoine, Adam, René, Bouché, Olivier

“…Background Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be…”
Get full text

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Chauvenet, Marion, Bécouarn, Yves, Houyau, Philippe, Aparicio, Thomas, Galais, Marie Pierre, Audemar, Franck, Assenat, Eric, Adenis, Antoine, Jouffroy-Zeller, Claire, Adam, Rene, Bouche, Olivier

“…Abstract only…”
Get full text

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial by Lopez-Crapez, Evelyne, Adenis, Antoine, Thezenas, Simon, Assenat, Eric, Francois, Eric, Guimbaud, Rosine, Chauvenet, Marion, Khemissa, Faiza, Audemar, Franck, Suc, Etienne, Rivoire, Michel, Ghiringhelli, François, Mercier-Blas, Anne, Mineur, Laurent, Becouarn, Yves, Houyau, Philippe, Stanbury, Trevor, Jouffroy-Zeller, Claire, Bouche, Olivier, Ychou, Marc

“…Abstract only…”
Get full text

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients by Oberic, Lucie, Vaillant, Willy, Hebraud, Benjamin, Recher, Christian, Suc, Etienne, Houyau, Philippe, Laurent, Guy, Ysebaert, Loic

“…Optimal treatment strategies are lacking in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Gemcitabine has shown activity and acceptable safety…”
Get full text

Multidisciplinary team meeting and EUSOMA quality indicators in breast cancer care: A French regional multicenter study by Pons-Tostivint, E., Daubisse-Marliac, L., Grosclaude, P., Oum sack, E., Goddard, J., Morel, C., Dunet, C., Sibrac, L., Lagadic, C., Bauvin, E., Bergé, Y., Bernard-Marty, C., Vaysse, C., Lacaze, J.L.L.

“…We evaluate breast cancer (BC) pathway at a regional level including public, private and university institutions. We assessed the quality of multidisciplinary…”
Get full text

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier-Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Moussata, Driffa, Becouarn, Yves, Houyau, Philippe, Aparicio, Thomas, Adam, Rene, Galais, Marie-Pierre, Audemar, Franck, Assenat, Eric, Stanbury, Trevor, Bouche, Olivier

“…Abstract only…”
Get full text

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial by Ravaud, A, Chevreau, C, Cany, L, Houyau, P, Dohollou, N, Roché, H, Soubeyran, P, Bonichon, F, Mihura, J, Eghbali, H, Tabah, I, Bui, B N

“…A randomized unblinded phase III trial was designed to determine the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) to accelerate…”
Get more information

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency by Houyau, P, Gay, C, Chatelut, E, Canal, P, Roché, H, Milano, G

Get more information